Teriflunomide Tablet, Film Coated
Product Images NDC 16729-400

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Teriflunomide (NDC 16729-400). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Accord Healthcare Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (14 mg Tablet Carton)

Teriflunomide Tablets 14 mg film-coated oral tablets packaging label by Accord Healthcare Inc. The label indicates 28 tablets per package, with the NDC 16729-400-76. It includes information about dosage, storage conditions, and manufacturer details, and features green text highlights on a white background.*

FDA Label Image

Principal Display Panel (14 mg Tablet Container)

Teriflunomide Tablets 14 mg film-coated oral tablets packaging label. The label includes the NDC 16729-400-09, indicates 28 tablets per package, and displays storage instructions and warnings. Manufactured by Intas Pharmaceuticals Limited and labeled for Accord Healthcare Inc.*

FDA Label Image

Principal Display Panel (7 mg Tablet Carton)

Teriflunomide Tablets 7 mg film-coated tablets packaging label. The carton contains 28 tablets and provides dosing instructions, storage conditions, and manufacturer information. Labeler is Accord Healthcare Inc. The label includes the NDC 16729-399-76 and states the product is Rx only.*

FDA Label Image

Principal Display Panel (7 mg Tablet Container)

Drug facts panel for Teriflunomide tablets, 7 mg strength. The panel includes dosage information, storage instructions, and a warning to keep out of reach of children. It also provides manufacturer and labeler details: manufactured by Intas Pharmaceuticals Limited in India and Accord Healthcare Inc. as the labeler. The package contains 28 film-coated tablets for oral use.*

FDA Label Image

Figure 1 (Teriflunomide Fig 01)

A line graph showing disability progression sustained for 12 weeks (%) over a period of 108 weeks in three groups: Placebo, 7 mg Teriflunomide, and 14 mg Teriflunomide. The y-axis represents percentage of disability progression, and the x-axis shows weeks. The graph includes numbers at risk for each group at various week intervals and highlights a statistically significant difference (p < 0.05) between 14 mg Teriflunomide and placebo.*

FDA Label Image

Figure 2 (Teriflunomide Fig 02)

A line graph showing disability progression sustained for 12 weeks (%) across approximately 108 weeks for three groups: placebo, 7 mg Teriflunomide, and 14 mg Teriflunomide. The graph includes a table of the number at risk for each group at multiple time points and notes a statistically significant difference for 14 mg Teriflunomide versus placebo (p < 0.05).*

FDA Label Image

Chemical Structure (Teriflunomide Str)

Chemical structure of Teriflunomide, the active ingredient. The structure shows the atomic arrangement and bonds in the Teriflunomide molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.